FDA advisors will meet later today discuss the possibility of authorising Pfizer and BioNTech's COVID-19 vaccine Comirnaty in children as young as five years old.
With positive phase 2/3 results for their COVID-19 vaccine Comirnaty in hand for the five to 11 age group, Pfizer and BioNTech are planning to move swiftly ahead with a filing for emergency
Orchard Therapeutics' gene therapy for rare childhood disease metachromatic leukodystrophy (MLD) Libmeldy has been rejected for NHS use by NICE in draft guidance.
Sanofi's Aubagio has become the first oral therapy approved for first-line use in children and adolescents with multiple sclerosis in the EU, a few days after the same indication was turned
Gilead Sciences has said it will start trials soon of its antiviral drug remdesivir in children – from newborns to adolescents – who have moderate-to-severe COVID-19.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.